Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases
Status:
COMPLETED
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the efficiency and safety of using combinations of antihyperlipidemic agents with a single drug to treat cardiovascular diseases.
The main questions it aims to answer are:
* Which approach is more effective rosuvastatin monotherapy or rosuvastatin ezetimibe combination antihyperlipidemic for patients with cardiovascular diseases (CVDs)?
* What medical problems do participants could when taking antihyperlipidemic drugs? Researchers will compare rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg to see the effectiveness and safety of these drugs in patients with CVDs.
Participants will:
* Patients will randomize to either rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg.
* Patients will be followed up to 12 weeks after starting treatment.
* All the patients will be subjected to: Full sheet taking, including detailed history and diagnosis of the case, Baseline Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) tests\& after 24 weeks of treatment, Lipid Profile, creatine kinase (CK) test, Creatine kinase-MB (CK-MB) test.